IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
39.1%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Edwards Lifesciences Corp (EW) receives a "Hold" rating with a composite score of 49.1/100, ranked #1321 out of 4446 stocks. Key factor scores: Quality 50/100, Value 51/100, Momentum 49/100. This is quantitative analysis only — not investment advice.
Edwards Lifesciences Corp (EW) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Edwards Lifesciences Corp Do?
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences Corp (EW) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael A. Mussallem and employs approximately 17,300 people, headquartered in Wilmington, California. With a market capitalization of $46.8B, EW is one of the prominent companies in the Healthcare sector.
Edwards Lifesciences Corp (EW) Stock Rating — Hold (April 2026)
As of April 2026, Edwards Lifesciences Corp receives a Hold rating with a composite score of 49.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.EW ranks #1,321 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Edwards Lifesciences Corp ranks #104 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
EW Stock Price and 52-Week Range
Edwards Lifesciences Corp (EW) currently trades at $77.87. The stock lost $1.28 (1.6%) in the most recent trading session. The 52-week high for EW is $87.89, which means the stock is currently trading -11.4% from its annual peak. The 52-week low is $65.94, putting the stock 18.1% above its annual trough. Recent trading volume was 4.9M shares, reflecting moderate market activity.
Is EW Overvalued or Undervalued? — Valuation Analysis
Edwards Lifesciences Corp (EW) carries a value factor score of 51/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 11.51x, compared to the Healthcare sector average of 23.63x — a discount of 51%. The price-to-book ratio stands at 4.51x, versus the sector average of 2.75x. The price-to-sales ratio is 7.96x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, EW trades at 31.84x EV/EBITDA, versus 6.34x for the sector.
Overall, EW's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Edwards Lifesciences Corp Profitability — ROE, Margins, and Quality Score
Edwards Lifesciences Corp (EW) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 39.1%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 29.5% versus the sector average of -33.1%.
On a margin basis, Edwards Lifesciences Corp reports gross margins of 78.6%, compared to 71.5% for the sector. The operating margin is 25.1% (sector: -66.1%). Net profit margin stands at 73.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
EW Debt, Balance Sheet, and Financial Health
Edwards Lifesciences Corp has a debt-to-equity ratio of 32.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.72x, indicating strong short-term liquidity. Cash and equivalents stand at $2.69B.
EW has a beta of 0.95, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Edwards Lifesciences Corp is 86/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Edwards Lifesciences Corp Revenue and Earnings History — Quarterly Trend
In TTM 2026, Edwards Lifesciences Corp reported revenue of $5.85B and earnings per share (EPS) of $1.84. Net income for the quarter was $4.05B. Gross margin was 78.6%. Operating income came in at $1.46B.
In FY 2025, Edwards Lifesciences Corp reported revenue of $6.07B and earnings per share (EPS) of $1.84. Net income for the quarter was $1.07B. Gross margin was 78.0%. Revenue grew 11.5% year-over-year compared to FY 2024. Operating income came in at $1.26B.
In Q3 2025, Edwards Lifesciences Corp reported revenue of $1.55B and earnings per share (EPS) of $0.50. Net income for the quarter was $290M. Gross margin was 77.8%. Revenue grew 14.7% year-over-year compared to Q3 2024. Operating income came in at $307M.
In Q2 2025, Edwards Lifesciences Corp reported revenue of $1.53B and earnings per share (EPS) of $0.57. Net income for the quarter was $332M. Gross margin was 77.5%. Revenue grew 10.6% year-over-year compared to Q2 2024. Operating income came in at $411M.
Over the past 8 quarters, Edwards Lifesciences Corp has demonstrated a growth trajectory, with revenue expanding from $1.39B to $5.85B. Investors analyzing EW stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
EW Dividend Yield and Income Analysis
Edwards Lifesciences Corp (EW) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
EW Momentum and Technical Analysis Profile
Edwards Lifesciences Corp (EW) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 29/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
EW vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing EW against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EW vs S&P 500 (SPY) comparison to assess how Edwards Lifesciences Corp stacks up against the broader market across all factor dimensions.
EW Next Earnings Date
No upcoming earnings date has been announced for Edwards Lifesciences Corp (EW) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy EW? — Investment Thesis Summary
Edwards Lifesciences Corp presents a balanced picture with arguments on both sides. Low volatility (stability score 86/100) reduces downside risk.
In summary, Edwards Lifesciences Corp (EW) earns a Hold rating with a composite score of 49.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EW stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Edwards Lifesciences Corp (EW) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Edwards Lifesciences (EW) receives a Hold rating, reflecting a balanced view of its strong market position in structural heart disease and critical care monitoring against a premium valuation. While the company exhibits robust profitability and revenue growth, its high P/E ratio relative to the healthcare sector suggests limited near-term upside, warranting caution for investors seeking immediate returns.
The core strength of Edwards lies in its innovative product portfolio and established presence in the transcatheter heart valve market, which drives consistent revenue growth. However, the current valuation appears to already incorporate these strengths, leaving less room for significant price appreciation. The most critical takeaway is that while Edwards is a fundamentally sound company, its current market price reflects much of its future potential, making it a hold for now.
Business Strategy & Overview
Edwards Lifesciences operates primarily in the structural heart disease and critical care monitoring sectors. The company's revenue is generated through the sale of transcatheter heart valve replacement and repair products, surgical structural heart solutions, and critical care monitoring systems. Edwards' strategic focus is on developing and commercializing innovative, minimally invasive therapies for heart valve disease, addressing a growing market driven by an aging population and increasing prevalence of cardiovascular conditions.
The company's product pipeline includes advancements in transcatheter mitral and tricuspid valve therapies, as well as next-generation aortic valves. Edwards invests heavily in research and development to maintain its technological leadership and expand its product offerings. This commitment to innovation is crucial for sustaining its competitive advantage and driving future growth.
Edwards distributes its products through a direct sales force and independent distributors, ensuring broad market access in the United States, Europe, Japan, and other international markets. The company's global presence allows it to capitalize on growth opportunities in emerging markets, where demand for advanced medical technologies is increasing.
The competitive landscape includes companies such as Medtronic, Abbott, and Boston Scientific, all of which offer competing products in the structural heart and critical care markets. Edwards differentiates itself through its focus on innovation, clinical evidence supporting its products, and strong relationships with key opinion leaders in the medical community. The company's strategy involves continuous product development, strategic acquisitions, and expansion into new geographic markets to maintain its leading position.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
12.1%
Sector: 10.6%
+13% VS SCTR
Economic Moat Analysis
Edwards Lifesciences possesses a narrow economic moat, primarily derived from intangible assets and switching costs. The company's intellectual property, including patents and proprietary technologies related to its transcatheter heart valve systems, creates a barrier to entry for competitors. These intangible assets protect Edwards' market share and allow it to command premium pricing for its innovative products.
Switching costs also contribute to the company's moat. Once hospitals and physicians become familiar with Edwards' products and procedures, they are less likely to switch to competing products due to the time and resources required for retraining and re-certification. This creates a degree of customer loyalty and reduces the risk of market share erosion.
However, the moat is considered narrow due to the presence of strong competitors with significant resources and established positions in the structural heart and critical care markets. Companies like Medtronic and Abbott are investing heavily in research and development and are actively developing competing products, which could erode Edwards' market share over time.
Furthermore, the regulatory environment and reimbursement policies can impact the company's competitive advantage. Changes in regulatory requirements or reimbursement rates could affect the adoption of Edwards' products and reduce its profitability. While Edwards has a strong track record of innovation and clinical evidence, it must continue to invest in research and development to maintain its technological leadership and defend its moat against increasing competition.
The company's reputation and brand recognition also play a role in its competitive advantage. Edwards has established a strong reputation for quality and reliability, which enhances its credibility with physicians and hospitals. This reputation is a valuable asset that contributes to its ability to maintain market share and command premium pricing.
Financial Health & Profitability
Edwards Lifesciences demonstrates strong financial health, characterized by consistent revenue growth, high margins, and a solid balance sheet. The company's revenue has grown steadily over the past several years, driven by increasing demand for its transcatheter heart valve systems and critical care monitoring products. The TTM revenue of $6.07 billion represents a 12.1% increase compared to the sector average of 10.7%.
The company's gross margin of 78.6% and operating margin of 25.1% are significantly higher than the healthcare sector averages of 71.9% and -65.2%, respectively, indicating efficient operations and strong pricing power. The net margin of 73.0% further underscores the company's profitability.
Edwards' balance sheet is healthy, with total cash of $2.69 billion and a current ratio of 3.72, indicating strong liquidity and the ability to meet its short-term obligations. The debt-to-equity ratio of 32.00 is slightly higher than the sector average of 30.00, but remains manageable given the company's strong cash flow generation.
Analyzing the quarterly financial history reveals a consistent trend of revenue and net income growth. While free cash flow data is unavailable for the TTM period, the negative free cash flow of $-486.06 million in FY2024 warrants further investigation. However, the strong profitability and revenue growth suggest that the company is generating sufficient cash flow to fund its operations and investments.
The company's return on equity (ROE) of 39.2% is significantly higher than the sector average of -42.5%, indicating efficient use of shareholder equity to generate profits. Overall, Edwards Lifesciences exhibits strong financial health, characterized by consistent revenue growth, high margins, and a solid balance sheet.
Valuation Assessment
Edwards Lifesciences' valuation is premium compared to the healthcare sector. The company's P/E ratio of 44.8x is significantly higher than the sector average of 24.3x, suggesting that investors are paying a premium for its earnings. Similarly, the EV/EBITDA ratio of 9.5x is higher than the sector average of 6.4x, indicating a higher valuation relative to its earnings before interest, taxes, depreciation, and amortization.
Given the company's strong revenue growth and profitability, a premium valuation is warranted. However, the current multiples suggest that the stock is fully valued, leaving limited room for significant price appreciation in the near term. The market appears to be pricing in continued strong growth and profitability, which may be difficult to sustain in the face of increasing competition and regulatory pressures.
A discounted cash flow (DCF) analysis would be necessary to determine the intrinsic value of the stock. However, based on the current multiples, it appears that the stock is trading at or above its fair value. Investors should exercise caution and consider the potential for multiple compression if growth slows or profitability declines.
The absence of free cash flow data makes a traditional FCF yield analysis impossible. However, the high P/E ratio and EV/EBITDA multiple suggest that the stock is not undervalued based on its current earnings. A more conservative valuation approach may be warranted, given the potential risks and uncertainties facing the company.
While Edwards Lifesciences is a high-quality company with a strong track record, its current valuation appears to be stretched. Investors should carefully consider the risks and potential rewards before investing in the stock.
Risk & Uncertainty
Edwards Lifesciences faces several specific risks and uncertainties that could impact its business and financial performance. One of the primary risks is increasing competition in the structural heart and critical care markets. Companies like Medtronic, Abbott, and Boston Scientific are investing heavily in research and development and are actively developing competing products, which could erode Edwards' market share and pricing power.
Regulatory risks also pose a significant threat. The medical device industry is heavily regulated, and changes in regulatory requirements or reimbursement policies could affect the adoption of Edwards' products and reduce its profitability. Delays in regulatory approvals for new products could also impact the company's growth prospects.
Product liability risks are inherent in the medical device industry. Edwards could face lawsuits and claims related to the safety and efficacy of its products, which could result in significant financial losses and reputational damage. The company's insurance coverage may not be sufficient to cover all potential liabilities.
Economic conditions and healthcare spending trends could also impact the company's performance. A slowdown in economic growth or a reduction in healthcare spending could reduce demand for Edwards' products and services. Changes in government healthcare policies, such as the Affordable Care Act, could also affect the company's business.
Finally, the company's reliance on a limited number of key products and customers could create concentration risks. A decline in demand for its transcatheter heart valve systems or the loss of a major customer could significantly impact its revenue and profitability.
Bulls Say / Bears Say
The Bull Case
BULL VIEWEdwards Lifesciences' strong market position in the rapidly growing transcatheter heart valve market ensures continued revenue growth and profitability.
BULL VIEWThe company's commitment to innovation and its robust product pipeline will drive future growth and maintain its competitive advantage.
The Bear Case
BEAR VIEWEdwards Lifesciences' premium valuation leaves limited room for upside, and the stock is vulnerable to multiple compression if growth slows.
BEAR VIEWIncreasing competition and regulatory pressures could erode the company's market share and profitability.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score EW and 4,400+ other equities.
Edwards Lifesciences Corp exhibits a 199% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
29.5%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
78.6%
Sector: 71.5%
Operating Margin
Core business profitability
25.1%
Sector: -66.1%
Net Margin
Bottom-line profitability
73.0%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
